Larazotide
Also known as: AT-1001, Larazotide Acetate, Tight Junction Modulator
A tight junction regulator peptide for celiac disease and intestinal permeability.
Overview
Larazotide acetate is an 8-amino acid peptide that regulates intestinal tight junctions. It was developed primarily for celiac disease to prevent gluten-induced intestinal permeability (leaky gut). It works locally in the GI tract without significant systemic absorption.
Mechanism of Action
Larazotide blocks zonulin receptors on intestinal epithelial cells, preventing tight junction disassembly. This maintains the intestinal barrier and reduces paracellular permeability triggered by gluten or other stressors.
Pharmacokinetics
Acts locally in the GI tract with minimal systemic absorption. Taken orally before meals containing gluten.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Clinical Trials
0.5-1 mg
Three times daily
Before meals
Taken 15 min before gluten exposure
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Reduced GI symptoms in celiac patients on gluten-free diet
- 2Decreased intestinal permeability markers
- 3Phase 3 trials for celiac disease completed
- 4Local GI action with minimal systemic effects
Side Effects & Contraindications
Reported Side Effects
- Headache (rare)
- Nausea (rare)
- Generally well-tolerated
Contraindications
- Hypersensitivity to components
Safety Considerations
Generally well-tolerated. Does not replace gluten-free diet for celiac patients. Minimal systemic absorption reduces side effect profile.
Storage Requirements
Room temperature
Scientific References
- 1